India is advancing with DengiAll, an indigenous single-shot dengue vaccine in late-stage trials in Delhi. This tetravalent vaccine aims to provide balanced protection against all four serotypes, addressing past vaccine challenges. Its single-dose design is intended for practical, universal prevention in a country with uneven healthcare access. While promising, real-world validation will depend on population exposure to all circulating strains, acknowledging the complex factors influencing dengue spread.